((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
acnltk.probability
FreqDist
p5
((dp6
S'heart study logistic regression coeffici'
p7
I1
sS'of peripheral alpha-1'
p8
I1
sS'doxazosin arm termin'
p9
I1
sS'arm of allhat'
p10
I1
sS'trial compar'
p11
I1
sS'plasma norepinephrin'
p12
I1
sS'terazosin'
p13
I3
sS'active-control tri'
p14
I1
sS'cardiac receptor'
p15
I1
sS'outcome of chd'
p16
I1
sS'second-line anti-hypertensive therapi'
p17
I1
sS'diverse patient popul'
p18
I1
sS'find'
p19
I2
sS'antihypertensive therapi'
p20
I1
sS'clinical present'
p21
I1
sS'plasma volume fluid expans'
p22
I1
sS'doxazosin arm'
p23
I3
sS'doxazosin arm of'
p24
I1
sS'myocardial damag'
p25
I1
sS'systolic blood'
p26
I3
sS'myocyt'
p27
I2
sS'harmful effect of'
p28
I1
sS'cellular injuri'
p29
I1
sS'assay'
p30
I1
sS'medical care survey'
p31
I1
sS'normotensive pati'
p32
I1
sS'express'
p33
I1
sS'peripheral alpha-1 antagonists for low'
p34
I1
sS'fluid'
p35
I1
sS'fractional excret'
p36
I1
sS'treatment of'
p37
I1
sS'low-dose chlorthalidon'
p38
I2
sS'cellular'
p39
I1
sS'of total mort'
p40
I1
sS'alpha-1'
p41
I1
sS'norepinephrin'
p42
I4
sS'for th'
p43
I1
sS'peripheral alpha-1'
p44
I14
sS'acute renal effect of prazosin'
p45
I1
sS'primary outcome of'
p46
I1
sS'prazosin blocks heat shock protein'
p47
I1
sS'cardiovascular diseas'
p48
I1
sS'total mort'
p49
I1
sS'fluid status peripheral alpha-1 antagonist'
p50
I1
sS'trial arm'
p51
I1
sS'symptomatic episod'
p52
I1
sS'allhat'
p53
I13
sS'hypertension therapi'
p54
I1
sS'comparative tri'
p55
I1
sS'framingham'
p56
I1
sS'wyeth'
p57
I1
sS'arm'
p58
I5
sS'prazosin arm'
p59
I1
sS'subject'
p60
I1
sS'cellular effects physiolog'
p61
I1
sS'excretion of sodium'
p62
I1
sS'treatment of mild hypertension studi'
p63
I1
sS'homeostasi'
p64
I1
sS'particip'
p65
I3
sS'endothelin-1'
p66
I1
sS'physiolog'
p67
I1
sS'ecfv'
p68
I1
sS'clinical epidemiology fellow'
p69
I1
sS'chronic sodium'
p70
I1
sS'cardiac damag'
p71
I1
sS'men'
p72
I1
sS'physiologic literatur'
p73
I2
sS'for prazosin'
p74
I1
sS'coeffici'
p75
I1
sS'congestive heart'
p76
I1
sS'treatment of mild hypertens'
p77
I1
sS'toler'
p78
I2
sS'epidemiology fellow'
p79
I1
sS'interpret'
p80
I1
sS'popul'
p81
I4
sS'search'
p82
I1
sS'fluid statu'
p83
I1
sS'chronic congestive heart'
p84
I1
sS'retent'
p85
I1
sS'fluid expans'
p86
I2
sS'trial'
p87
I15
sS'survey'
p88
I1
sS'committe'
p89
I1
sS'allhat particip'
p90
I1
sS'lipid-lowering treat'
p91
I1
sS'studi'
p92
I5
sS'subclinical ventricular dysfunct'
p93
I1
sS'heart failure occurr'
p94
I1
sS'episod'
p95
I1
sS'heart'
p96
I7
sS'clonidin'
p97
I2
sS'study logistic regression coeffici'
p98
I1
sS'of prazosin'
p99
I2
sS'framingham heart study logistic regression coeffici'
p100
I1
sS'framingham heart study logist'
p101
I1
sS'blockad'
p102
I1
sS'jnc vi'
p103
I1
sS'study popul'
p104
I1
sS'peripheral alpha-1 antagonists for'
p105
I1
sS'damag'
p106
I2
sS'of heart'
p107
I1
sS'chd'
p108
I1
sS'lund-johansen'
p109
I1
sS'chf'
p110
I8
sS'injuri'
p111
I2
sS'peripheral alpha-1 antagonists for lowering blood'
p112
I1
sS'lipid-low'
p113
I1
sS'fractional excretion of'
p114
I1
sS'recommend'
p115
I1
sS'sodium homeostasi'
p116
I1
sS'heart attack'
p117
I1
sS'routine use of'
p118
I1
sS'acute renal effect of'
p119
I1
sS'diastolic blood'
p120
I1
sS'fractional excretion of sodium'
p121
I1
sS'subclinical diseas'
p122
I1
sS'hypertension studi'
p123
I1
sS'efficaci'
p124
I1
sS'shep trial'
p125
I3
sS'erst'
p126
I1
sS'cardiovascular outcom'
p127
I1
sS'inhibit'
p128
I1
sS'endpoint'
p129
I4
sS'physiology studi'
p130
I1
sS'cellular repair'
p131
I1
sS'ramif'
p132
I1
sS'randomized tri'
p133
I1
sS'english-language pap'
p134
I1
sS'outcom'
p135
I2
sS'national ambulatory medical care survey'
p136
I1
sS'arm termin'
p137
I1
sS'hypertrophi'
p138
I1
sS'va'
p139
I1
sS'complic'
p140
I1
sS'tolerability tri'
p141
I1
sS'histologic evid'
p142
I1
sS'vi'
p143
I1
sS'von'
p144
I1
sS'clinical heart failure ev'
p145
I1
sS'physiologic studi'
p146
I2
sS'trial comparing atenolol'
p147
I1
sS'peripheral alpha-1 antagonist'
p148
I17
sS'epidemiologic research'
p149
I1
sS'shep particip'
p150
I1
sS'chronic therapi'
p151
I2
sS'captopril'
p152
I2
sS'risk'
p153
I2
sS'low-dose diuret'
p154
I3
sS'cohort'
p155
I1
sS'differenti'
p156
I1
sS'fluid status peripheral alpha-1'
p157
I1
sS'pharmacologic treat'
p158
I1
sS'benign prostatic hypertrophi'
p159
I1
sS'concentration of'
p160
I1
sS'allhat popul'
p161
I1
sS'hypertens'
p162
I1
sS'clinical presentation of'
p163
I1
sS'higher'
p164
I1
sS'of norepinephrin'
p165
I1
sS'evid'
p166
I2
sS'ser clinical epidemiology fellow'
p167
I1
sS'expans'
p168
I6
sS'of allhat'
p169
I1
sS'prostatism evid'
p170
I1
sS'cellular effects physiologic studi'
p171
I1
sS'blood'
p172
I2
sS'associ'
p173
I1
sS'heart failure find'
p174
I1
sS'the pharmacologic treat'
p175
I1
sS'secondary outcom'
p176
I2
sS'original baselin'
p177
I1
sS'rat myocyt'
p178
I1
sS'framingham heart study logistic regress'
p179
I1
sS'national ambulatori'
p180
I1
sS'attack tri'
p181
I1
sS'withdraw'
p182
I2
sS'secondary outcome of total mort'
p183
I1
sS'load'
p184
I2
sS'life-prolonging therapi'
p185
I1
sS'comparing atenolol'
p186
I1
sS'prazosin decreas'
p187
I1
sS'blocker'
p188
I1
sS'dose'
p189
I1
sS'jnc'
p190
I1
sS'intensive dietary counsel'
p191
I1
sS'clinic'
p192
I1
sS'paper'
p193
I1
sS'fluid status peripher'
p194
I1
sS'clinical presentation of heart'
p195
I1
sS'demograph'
p196
I1
sS'routine use of peripheral alpha-1'
p197
I1
sS'concentr'
p198
I1
sS'sodium'
p199
I5
sS'prazosin blocks heat shock protein express'
p200
I1
sS'stimul'
p201
I1
sS'radioisotopic assay'
p202
I1
sS'dysfunct'
p203
I1
sS'potential associ'
p204
I1
sS'va cooperative studi'
p205
I1
sS'treatment'
p206
I4
sS'ventricular dysfunct'
p207
I1
sS'fluid retent'
p208
I1
sS'secondary outcome of'
p209
I1
sS'absolute risk reduction for clinical heart'
p210
I1
sS'plasma'
p211
I1
sS'concentration of norepinephrin'
p212
I1
sS'therapi'
p213
I6
sS'loss'
p214
I4
sS'myocardial injuri'
p215
I1
sS'nation'
p216
I2
sS'cardiovascular endpoint'
p217
I4
sS'antihypertens'
p218
I3
sS'peripher'
p219
I1
sS'framingham heart'
p220
I1
sS'mmhg'
p221
I1
sS'bph'
p222
I2
sS'hydrochlorothiazid'
p223
I2
sS'care survey'
p224
I1
sS'hypertensive pati'
p225
I2
sS'doxazosin gain'
p226
I1
sS'expansion for'
p227
I1
sS'routine use of peripheral alpha-1 antagonist'
p228
I1
sS'doxazosin arm of allhat'
p229
I1
sS'alpha-1 antagonist'
p230
I17
sS'absolute risk'
p231
I1
sS'dietary counsel'
p232
I1
sS'logistic regression coeffici'
p233
I1
sS'von willebrand'
p234
I1
sS'epidemiolog'
p235
I2
sS'laboratori'
p236
I1
sS'primary outcom'
p237
I1
sS'of doxazosin'
p238
I2
sS'medlin'
p239
I2
sS'patient popul'
p240
I1
sS'shep'
p241
I4
sS'mmhg higher'
p242
I1
sS'doxazosin'
p243
I13
sS'event'
p244
I5
sS'baselin'
p245
I2
sS'for'
p246
I1
sS'expansion for prazosin'
p247
I2
sS'renal effect of prazosin'
p248
I1
sS'research'
p249
I1
sS'profil'
p250
I1
sS'atenolol'
p251
I3
sS'myocardium'
p252
I1
sS'occurr'
p253
I2
sS'vascular hormon'
p254
I1
sS'diseas'
p255
I2
sS'patient'
p256
I3
sS'national committe'
p257
I1
sS'diltiazem'
p258
I1
sS'nonfatal heart failure ev'
p259
I1
sS'cholesterol'
p260
I2
sS'rahway'
p261
I1
sS'bibliographic search'
p262
I1
sS'ambulatory medical care survey'
p263
I1
sS'heart attack tri'
p264
I1
sS'chlorthalidon'
p265
I6
sS'relative risk'
p266
I1
sS'heart failure ev'
p267
I2
sS'doxazosin unmasking incipient heart'
p268
I1
sS'neurohormon'
p269
I1
sS'beta receptor stimul'
p270
I1
sS'diastolic hypertens'
p271
I1
sS'of'
p272
I2
sS'literatur'
p273
I1
sS'nonfatal heart'
p274
I1
sS'tomh'
p275
I1
sS'cardiovascular ev'
p276
I1
sS'clinical heart'
p277
I1
sS'mortal'
p278
I1
sS'prostat'
p279
I3
sS'national ambulatory medical car'
p280
I1
sS'total body sodium'
p281
I2
sS'perturb'
p282
I1
sS'beta block'
p283
I1
sS'clinical tri'
p284
I2
sS'receptor'
p285
I3
sS'lipid profil'
p286
I1
sS'diverse pati'
p287
I1
sS'diuret'
p288
I7
sS'prazosin'
p289
I5
sS'outcome of total mort'
p290
I1
sS'harmful effect of doxazosin'
p291
I1
sS'primary outcome of chd'
p292
I1
sS'termin'
p293
I3
sS'of sodium'
p294
I1
sS'shock protein express'
p295
I3
sS'kaplan-meier curv'
p296
I1
sS'status peripheral alpha-1 antagonist'
p297
I1
sS'gain'
p298
I6
sS'chlorthalidone arm'
p299
I2
sS'apoptosi'
p300
I1
sS'cooperative studi'
p301
I1
sS'symptom'
p302
I1
sS'chronic volume load'
p303
I1
sS'person-year'
p304
I2
sS'counsel'
p305
I1
sS'national ambulatory med'
p306
I1
sS'cardiotox'
p307
I1
sS'merck'
p308
I1
sS'cardiovascular compl'
p309
I1
sS'framingham heart studi'
p310
I1
sS'beta receptor'
p311
I2
sS'dose diuret'
p312
I1
sS'curv'
p313
I1
sS'for the pharmacologic treat'
p314
I3
sS'prostatic hypertrophi'
p315
I1
sS'absolute risk reduction for'
p316
I1
sS'protein express'
p317
I1
sS'plasma volume fluid'
p318
I1
sS'chronic sodium homeostasi'
p319
I1
sS'fellow'
p320
I1
sS'decreas'
p321
I1
sS'mild hypertension studi'
p322
I1
sS'of chd'
p323
I1
sS'nj'
p324
I1
sS'double-blind'
p325
I1
sS'antihypertensive efficaci'
p326
I1
sS'of peripheral alpha-1 antagonist'
p327
I5
sS'beta-block'
p328
I1
sS'receptor stimul'
p329
I1
sS'first-line blood'
p330
I1
sS'prazosin blocks heat shock'
p331
I1
sS'low-dose chlorthalidone arm'
p332
I1
sS'anti-hypertensive therapi'
p333
I1
sS'hormon'
p334
I1
sS'of mild hypertension studi'
p335
I1
sS'allhat tri'
p336
I2
sS'receptor inhibit'
p337
I1
sS'rr'
p338
I3
sS'antagonist'
p339
I20
sS'va coop'
p340
I1
sS'regression coeffici'
p341
I1
sS'treatment of mild'
p342
I1
stp343
Rp344
tp345
.